Clinical trial NCT03415659: Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors
Official title: A Phase I, Open-label, Single-center, Single/Multiple-dose, Dose-escalation/Dose-expansion Clinical Study on Tolerance and Pharmacokinetics of HWH340 Tablet in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Solid Tumors
HRD
BRCA Mutation
Keywords: HWH340
pharmacokinetics
dose-escalation
safety
efficacy
dose-expansion
Lead sponsor: Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
Sponsor class: OTHER
First posted: 2018-01-30
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, dose-escalation/dose-expansion, phase I clinical trial study to investigate the safety, tolerability, and efficacy of HWH340. In addition, the pharmacokinetic characteristics will also be investigated. Three parts are included in this study.

Detailed description: Part one is a single-dose study on tolerance and pharmacokinetics, in which 21-42 patients with advanced solid tumors would be enrolled. Patients will receive escalating dose groups of HWH340 tablet.

Part two is a multiple-dose study on tolerance and pharmacokinetics. Based on the safety assessment, three or four groups would be chosen to conduct the study. 9-24 patients with advanced solid tumors will be enrolled.

Part three is a dose expansion stage on safety and efficacy. Two to four dose-groups would be chosen to conduct the study. 40-60 patients with advanced solid tumors with BRCA mutation OR homologous recombination deficiency (HRD) will be enrolled.

Eligibility criteria: Inclusion Criteria:

* Patients with the advanced solid tumors, which have been histologically and/ or cytologically confirmed.
* Patients with advanced solid tumors refractory to standard therapy or for whom no suitable effective standard therapy exists.
* patients in dose expansion stage must meet the following conditions:
* Group 1: Germline and/or systemic BRCA1/2 mutation;
* Group 2: HRD related gene (except BRCA 1/2) mutation;
* For breast cancer patients, Histologically or cytologically confirmed HER2(-), and received ≤3 prior lines of chemotherapy in advanced or metastatic setting;
* 18 ≤ years of age ≤ 70
* Expected survival time ≥ 6 months
* No serious hematopoietic dysfunction exists. Also, normal function of bone marrow and organs such as heart, lung, liver and kidney are required. Within 14 days prior to inclusion, the patients' laboratory examination results must be within normal limits(under the condition of no extra growth factor or blood transfusion): Blood routine examination: Absolute neutrophil count( ANC) ≥ 1.5 × 109/L),Platelets(PLT) ≥ 100 × 109/L, Hemoglobin(Hb) ≥ 100 g/L;Renal function: Serum creatinine (Cr) ≤1.5×ULN ;Hepatic function: Total Bilirubin ≤1.5×ULN, AST and ALT ≤ 2.5 ×ULN (For patients with liver metastases, AST and ALT ≤ 5 × ULN) ;Electrolytes: normal value ranges (sodium, potassium and calcium);Coagulation function: International Normalized Ratio( INR) ≤1.5, Activated partial thromboplastin time(APTT) ≤ 1.5 × ULN;
* Patients of reproductive potential must agree to practice effective medically approved contraceptive methods during the trial and 6 months afterwards. Women of childbearing potential must have a negative pregnancy test within 7 days prior to screening.
* Subject must fully understand this study, sign informed consent on a voluntary basis , comply with procedures and follow-up examinations as outlined in the protocol and agree to have the gene test.
* Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2 (patients in the multiple-dose study)
* Multiple-dose patients must have no less than one measurable tumor according to RECIST 1.1 criteria.

Exclusion Criteria:

* Subject who has other serious and/or uncontrollable damaged vital organs or unstable systemic disease besides tumors. These diseases include but not limit to uncontrolled diabetes, unstable angina pectoris , cerebrovascular accident or transient cerebral ischemia( within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart-failure , uncontrolled high blood pressure, active or uncontrollable infection, hepatic/renal/metabolic disease, serious gastrointestinal disease, any mental disease that may affect study abidance ; or any medical conditions, which in the opinion of the study investigators, places the subject at an unacceptably high risk of toxicities and interfere with the study.
* Subject who has previously been treated with PARP inhibitors, including any related clinical trials, except for HWH340. Subjects in dose expansion stage who have previously received PARP inhibitors (including drug clinical trials), except for patients who have not reached a therapeutic dose with a PARP inhibitor, or patients who have used a PARP inhibitor which is not first-line treatment for ≤ 28 days;
* Subject who has received the treatments of inhibitors of CYP3A3 and/or CYP2D6 within 2 weeks.
* Subject who has received chemotherapy, radiotherapy, endocrinotherapy, biotherapy, immunotherapy, Chinese herbal treatment or other anti-tumor treatment within 4 weeks prior to initiation of this study.In the dose expansion stage, except for patients who have begun bisphosphonate or RANK-L inhibitors with stable dose for bone metastases before enrollment.
* Subject who has participated in other clinical trials or used other investigational drug within 3 weeks prior to initiation of this study.
* Subject who has the autoimmune disease, immunodeficiency disease or surgical history of organ transplantation.
* Positive results of HBsAg, HCV antibody, HIV antibody or Syphilis. Patient who has chronic toxic reaction (≥ CTCAE Grade 2) caused by prophase treatment, except the hair-loss patients.
* Subject who has experienced major surgery and has not been fully rehabilitated within 4 weeks prior to this study.
* Subject who is allergic to the investigational drug or similar drugs, or has the history of allergic disease, or is in allergic constitution.
* History of alcohol addiction or abuse.
* Pregnant /lactating women.
* Subject who has the symptoms of CNS metastases.
* History of gastrointestinal dysfunction and difficulty in swallowing that may influence the drug absorption.
* Subject who has received blood transfusion within 4 weeks prior to the study.
* Subject who attends the study is not on a voluntary basis or cannot comply with the protocol.
* Judged by the investigator, for any reason, that the subject is an unsuitable candidate.

Primary outcomes:
measure: Maximum tolerated dose (MTD) and recommended dose (RD) by evaluating the safety and tolerability on single dose
timeFrame: up to 7 days after dosing
measure: Number of Participants With Laboratory Test Abnormalities on single dose
timeFrame: up to 7 days after dosing
measure: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) on multiple dose
timeFrame: up to 30 days after dosing
measure: Number of Participants With Laboratory Test Abnormalities on multiple dose
timeFrame: up to 30 days after dosing
Secondary outcomes:
measure: Maximum Observed Plasma Concentrations of platinum (Cmax)
timeFrame: Prior to 0 hour, and 0.5, 1, 2, 4, 8, 12, 36 and 48 hours post dose
measure: Tumor Objective Response Rate（ORR）
timeFrame: on day 42 post dose
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: Prior to 0 hour, and 0.5, 1, 2, 4, 8, 12, 36 and 48 hours post dose
measure: Time for Maximum Observed Plasma Concentration (Tmax)
timeFrame: Prior to 0 hour, and 0.5, 1, 2, 4, 8, 12, 36 and 48 hours post dose
measure: Disease Control Rate (DCR)
timeFrame: through study completion, an average of 1 year
measure: Objective Response Rate by Investigator
timeFrame: through study completion, an average of 1 year
measure: Disease control rate
timeFrame: through study completion, an average of 1 year
measure: Duration of response
timeFrame: through study completion, an average of 1 year
measure: Best overall response
timeFrame: through study completion, an average of 1 year
measure: Progression Free Survival
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin medical university cancer insititute & hospital
state: Tianjin
Study officials:
affiliation: Professor of Medicine
name: TONG Zhongsheng
role: PRINCIPAL_INVESTIGATOR
References: